Previous 10 | Next 10 |
There’s only one week left until we turn the page on June and the second quarter. With GDP numbers and more CPI data expected to show the progress in curbing inflation, the market’s risk appetite seems to change daily. But one of the more static trends in the stock market toda...
Invitae, a next-gen healthcare/biotech company, has seen its stock getting hammered due to strong worries about a looming bankruptcy due to reckless cash burn. However, in the last few quarters, the company has started to shift from growth-at-all-costs to focusing on reducing the cash...
Genetic medical testing specialist Invitae (NYSE: NVTA) didn't pass the investment test for one researcher late on Thursday. The following day its stock took a more than 15% hit because of this estimation. After market hours on Thursday, financial services company Piper Sandle...
Gainers: Turning Point Therapeutics (TPTX) +117%. Energy Focus (EFOI) +40%. Galecto (GLTO) +25%. Adaptimmune (ADAP) +22%. Amylyx Pharmaceuticals (AMLX) +22%. AudioEye (AEYE) +20%. Sprague Resources LP (SRLP) +20%. Global Cord Blood (CO) +18%. GreenBox (GBOX) +17%. Kopin (KOPN) +15%. Losers: N...
Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...
Invitae is a truly hyped-up story stock. When growth is slowing and you have no profitability to show for it, the market's hammering of NVTA stock is well-justified. We urge investors to be cautious in our previous article and beware of its hype. The stock has fallen almost 90% since ...
New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access PR Newswire - New data to be presented by Invitae at 2022 ASCO Annual Meeting show importance of genetic testing for all cancer patients - S...
Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...
Biotech companies spend a lot of money. They spend it on research and development, clinical trials, and (if they are lucky) marketing and a salesforce. Bringing a new pharmaceutical or medical device to market is an expensive proposition. In fact, it's fair to say that a lot of biotech comp...
Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel PR Newswire - New 38-gene testing panel and clinical decision support tool analyzes a patient's genetics and co-medications for their impact on drug and dose personalization - SA...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...